
Jan 15 (Reuters) - Ocugen Inc OCGN.O:
OCUGEN ANNOUNCES POSITIVE PRELIMINARY PHASE 2 DATA FROM OCU410 MODIFIER GENE THERAPY FOR GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION
OCUGEN INC - NO SERIOUS ADVERSE EVENTS REPORTED IN PHASE 1 AND 2 TRIALS
OCUGEN INC - PHASE 2 SHOWS 46% LESION GROWTH REDUCTION VERSUS CONTROL
OCUGEN INC: REPORTING FULL DATA FROM OCU410 PHASE 2 CLINICAL TRIAL LATER THIS QUARTER AND INITIATING PHASE 3 IN 2026
OCUGEN INC: COMPANY REMAINS ON TRACK FOR A BIOLOGICS LICENSE APPLICATION (BLA) FILING FOR OCU410 IN 2028